165 related articles for article (PubMed ID: 24390418)
1. Role of HER2 status in the treatment for brain metastases arising from breast cancer with stereotactic radiosurgery.
Tam M; Narayana A; Raza S; Kunnakkat S; Golfinos JG; Parker EC; Novik Y
Med Oncol; 2014 Feb; 31(2):832. PubMed ID: 24390418
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases.
Parsai S; Miller JA; Juloori A; Chao ST; Kotecha R; Mohammadi AM; Ahluwalia MS; Murphy ES; Barnett GH; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
J Neurosurg; 2019 Feb; 132(2):503-511. PubMed ID: 30738402
[TBL] [Abstract][Full Text] [Related]
3. Impacts of HER2-overexpression and molecular targeting therapy on the efficacy of stereotactic radiosurgery for brain metastases from breast cancer.
Yomo S; Hayashi M; Cho N
J Neurooncol; 2013 Apr; 112(2):199-207. PubMed ID: 23296546
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer subtype affects patterns of failure of brain metastases after treatment with stereotactic radiosurgery.
Vern-Gross TZ; Lawrence JA; Case LD; McMullen KP; Bourland JD; Metheny-Barlow LJ; Ellis TL; Tatter SB; Shaw EG; Urbanic JJ; Chan MD
J Neurooncol; 2012 Dec; 110(3):381-8. PubMed ID: 23001361
[TBL] [Abstract][Full Text] [Related]
5. Salvage stereotactic radiosurgery for breast cancer brain metastases: outcomes and prognostic factors.
Kelly PJ; Lin NU; Claus EB; Quant EC; Weiss SE; Alexander BM
Cancer; 2012 Apr; 118(8):2014-20. PubMed ID: 21918959
[TBL] [Abstract][Full Text] [Related]
6. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
Miller JA; Kotecha R; Ahluwalia MS; Mohammadi AM; Chao ST; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
Cancer; 2017 Jun; 123(12):2283-2293. PubMed ID: 28192598
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis.
Kim JM; Miller JA; Kotecha R; Chao ST; Ahluwalia MS; Peereboom DM; Mohammadi AM; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Abraham J; Moore H; Budd GT; Suh JH
Neuro Oncol; 2019 May; 21(5):659-668. PubMed ID: 30726965
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases.
Mills MN; Walker C; Thawani C; Naz A; Figura NB; Kushchayev S; Etame A; Yu HM; Robinson TJ; Liu J; Vogelbaum MA; Forsyth PA; Czerniecki BJ; Soliman HH; Han HS; Ahmed KA
BMC Cancer; 2021 Mar; 21(1):223. PubMed ID: 33663447
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine and stereotactic radiation in the management of breast cancer brain metastases.
Mills MN; Naz A; Thawani C; Walker C; Figura NB; Kushchayev S; Oliver DE; Etame AB; Yu HM; Robinson TJ; Liu JKC; Vogelbaum MA; Forsyth PA; Czerniecki BJ; Soliman HH; Han HS; Ahmed KA
BMC Cancer; 2021 May; 21(1):552. PubMed ID: 33992087
[TBL] [Abstract][Full Text] [Related]
10. Tucatinib and stereotactic radiosurgery in the management of HER2 positive breast cancer brain metastases.
Khatri VM; Mills MN; Oliver DE; Yu HM; Vogelbaum MA; Forsyth PA; Soliman HH; Han HS; Ahmed KA
J Neurooncol; 2023 Aug; 164(1):191-197. PubMed ID: 37490232
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer subtype as a predictor for outcomes and control in the setting of brain metastases treated with stereotactic radiosurgery.
Grubb CS; Jani A; Wu CC; Saad S; Qureshi YH; Nanda T; Yaeh A; Rozenblat T; Sisti MB; Bruce JN; McKhann GM; Sheth SA; Lesser J; Cheng SK; Isaacson SR; Lassman AB; Connolly EP; Wang TJ
J Neurooncol; 2016 Mar; 127(1):103-10. PubMed ID: 26615564
[TBL] [Abstract][Full Text] [Related]
12. Treating Brain Metastases from Breast Cancer: Outcomes after Stereotactic Radiosurgery.
Wilson TG; Robinson T; MacFarlane C; Spencer T; Herbert C; Wade L; Reed H; Braybrooke JP
Clin Oncol (R Coll Radiol); 2020 Jun; 32(6):390-396. PubMed ID: 32131980
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic radiosurgery using the Leksell Gamma Knife Perfexion unit in the management of patients with 10 or more brain metastases.
Grandhi R; Kondziolka D; Panczykowski D; Monaco EA; Kano H; Niranjan A; Flickinger JC; Lunsford LD
J Neurosurg; 2012 Aug; 117(2):237-45. PubMed ID: 22631694
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer. Clinical article.
Kondziolka D; Kano H; Harrison GL; Yang HC; Liew DN; Niranjan A; Brufsky AM; Flickinger JC; Lunsford LD
J Neurosurg; 2011 Mar; 114(3):792-800. PubMed ID: 20887087
[TBL] [Abstract][Full Text] [Related]
15. CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases.
Figura NB; Potluri TK; Mohammadi H; Oliver DE; Arrington JA; Robinson TJ; Etame AB; Tran ND; Liu JK; Soliman H; Forsyth PA; Sahebjam S; Yu HM; Han HS; Ahmed KA
J Neurooncol; 2019 Sep; 144(3):583-589. PubMed ID: 31399935
[TBL] [Abstract][Full Text] [Related]
16. Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases.
Singh C; Qian JM; Yu JB; Chiang VL
J Neurosurg; 2019 Feb; 132(2):512-517. PubMed ID: 30771783
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.
Braccini AL; Azria D; Thezenas S; Romieu G; Ferrero JM; Jacot W
Breast; 2013 Oct; 22(5):993-8. PubMed ID: 23831232
[TBL] [Abstract][Full Text] [Related]
18. Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥ 2 cm.
Angelov L; Mohammadi AM; Bennett EE; Abbassy M; Elson P; Chao ST; Montgomery JS; Habboub G; Vogelbaum MA; Suh JH; Murphy ES; Ahluwalia MS; Nagel SJ; Barnett GH
J Neurosurg; 2018 Aug; 129(2):366-382. PubMed ID: 28937324
[TBL] [Abstract][Full Text] [Related]
19. The use of stereotactic radiosurgery for brain metastases from breast cancer: who benefits most?
Cho E; Rubinstein L; Stevenson P; Gooley T; Philips M; Halasz LM; Gensheimer MF; Linden HM; Rockhill JK; Gadi VK
Breast Cancer Res Treat; 2015 Feb; 149(3):743-9. PubMed ID: 25638395
[TBL] [Abstract][Full Text] [Related]
20. Relationship between HER2 status and prognosis in women with brain metastases from breast cancer.
Xu Z; Marko NF; Chao ST; Angelov L; Vogelbaum MA; Suh JH; Barnett GH; Weil RJ
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e739-47. PubMed ID: 22024205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
